Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UBA52P3 stands for "ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 3" and represents a member of the processed pseudogenes derived from the functional UBA52 gene, which encodes a fusion of ubiquitin and ribosomal protein L40[2][3]. Pseudogenes like UBA52P3 have accumulated mutations (such as nucleotide substitutions and deletions) that disrupt their open reading frames, rendering them incapable of producing a functional protein[2]. The UBA52 pseudogene family in humans includes one functional gene (UBA52) and approximately eight processed pseudogenes[2]. While some pseudogenes can occasionally be transcribed or even translated in atypical scenarios, there is no evidence for UBA52P3 having a functional or therapeutic role, nor is it currently considered a drug target or relevant biomarker[2][3]. Although the functional UBA52 gene is involved in important cellular processes such as protein synthesis and regulation of tumorigenesis and autophagy[1], UBA52P3 is only a pseudogene derivative, not encoding a functional protein. Pseudogenes like UBA52P3 are generally believed to be nonfunctional remnants with no established biological function or disease association[2][3]. Occasionally, expression or translation from pseudogenes has been reported in other genetic contexts, but there is no data suggesting this is relevant for UBA52P3. There is nothing to indicate UBA52P3 itself is considered a therapeutic target, receptor, enzyme, transporter, or has any notable involvement in drug response or human disease. UBA52P3 is a processed pseudogene with no established function, not a druggable target, and is not associated with disease, drugs, or biological pathways. The entry is for a pseudogene, not a functional gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 3 (UBA52P3).